EarningsQ2 2026 Earnings Report
MX:MUV2N Q2 2026 EPS Results
Actual EPS$357.84
Consensus EPS$292.00
Beat/MissBeat by +$65.84
One Year Ago EPS$325.94
MX:MUV2N Q2 2026 Revenue Results
Actual Revenue$381.24B
Expected Revenue$335.36B
Beat/MissBeat by +$45.88B
YoY Revenue Growth+6.38%
Earnings Announcement Details
QuarterQ2 2026
Date08/07/2026
TimeBefore Open
Conference CallFriday, August 7, 2026
MX:MUV2N Upcoming Earnings
Munich Reinsurance's next earnings date is estimated for November 12, 2026, based on past reporting schedules.
Q2 2026 Earnings Call Audio
No earnings call audio is available for this earnings event.
Q2 2026 Earnings Slide Deck
No slide deck is available for this earnings event.
Q2 2026 Earnings Call Summary
Earnings Call Sentiment|Positive
The call presents strong financial and operating performance across multiple areas (net income, ROE, investment returns, Life & Health technical results, GSI and ERGO contributions, and a very strong solvency position). These positives are moderated by meaningful near-term reinsurance market headwinds: a EUR 2 billion reduction in reinsurance revenue guidance, rising normalized P&C combined ratios (around 82% and trending up), volume declines in July renewals (≈-9%) and reliance on favorable loss experience and markets. Management emphasizes disciplined underwriting, capital strength and diversification to manage the cycle and preserve earnings targets. On balance, the company appears well positioned but faces clear near-term top-line and P&C margin challenges that are being actively managed.Company Guidance
Strong first-half net result and ROE
Net result of EUR 3.9 billion in H1 2026 (already >60% of full-year net income guidance) and return on equity of 23%, comfortably above the Ambition 2030 target of >18%.
Robust investment performance
Q2 return on investment 5.5%; running yield 4.0%; reinvestment yield 4.3%; 6-month ROI of 4.2%, ahead of full-year guidance (>3.5%). Private equity performance contributed positively.
Life & Health Re outperformance and strong CSM base
Life & Health reinsurance delivered a Q2 total technical result of EUR 528 million and H1 total technical result > EUR 1 billion. CSM stock reached EUR 16 billion, supporting sustainable future earnings; continued successful transactional and longevity business (e.g., EUR 4 billion longevity deal).
GSI and ERGO delivering profitable growth
Global Specialty Insurance: historical growth (~EUR 800 million p.a. through 2024) and robust combined ratios (H1 combined ratio 86.3%, Q2 88.9%) with organic growth close to the lower end of the 5%-9% Ambition 2030 range. ERGO: strong Q2 net result of EUR 321 million (Germany EUR 235 million; International EUR 86 million); ERGO NEXT integration progressing and digital/AI initiatives driving efficiency.
High solvency and capital flexibility
Economic Solvency II ratio increased to 304% in Q2, providing substantial capital flexibility to support underwriting and shareholder returns (dividends and buybacks).
Disciplined underwriting and portfolio diversification
Management emphasized strict underwriting discipline (willingness to walk away from inadequate pricing), and growth in GSI, Life Re and ERGO offsets P&C Re revenue decline on a currency-adjusted basis, strengthening earnings resilience.
July renewals and market discipline
July renewals showed no acceleration in rate softening vs April; wordings and structures held firm. Reported price change -5.5% in July (including ~1ppt negative mix effect) and Munich Re actively redeployed capacity to attractive opportunities.
MX:MUV2N Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed